Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2005

View Archived Issues

GSK report on a novel agonist of LXRalpha and -beta

Octaparin exerts antithrombotic effect without impairment of hemostasis in animal models

Pharmacokinetics/pharmacodynamics of oral direct thrombin inhibitor TGN-167

Clinical evidence supports the use of tecadenoson in the management of PSVT

TA-CD shows efficacy in reducing drug use in cocaine-dependent subjects

Product highlights at Serono

NGX-267 for Alzheimer's disease enters phase I study

Solvay and Mayo Clinic collaborate on gastrointestinal motility disorders

NexBio receives SBIR grant for Fludase testing

Ark reports breakthrough in targeted gene therapy delivery

Genelabs advances two nonnucleoside compounds for HCV

Bicifadine begins new phase III trial for postoperative pain

Preclinical and clinical study data presented on novel antiplatelet agent CS-747

Interim safety results of pivotal study of NX-1207 for BPH

Positive phase II results for ICX-PRO advance program into phase III

Valortim cleared for phase I study

Isis and Lilly extend antisense drug discovery collaboration

TH-070 begins phase III study for BPH

Phase I study of ARRY-334543 in cancer patients cleared to begin

New phase I antiviral study of Tarvacin for HCV

Inflazyme receives FDA feedback on phase III studies for IPL-512602

Tanogitran demonstrates a superior efficacy profile than melagatran in vitro

CT-011 shows promise in the management of advanced hematological malignancies

Recent patents disclose novel analgesic and anesthetic agents

New anti-HIV agents described in recent Pfizer patent

Novel agents for metabolic disorders in early development

New DPP-IV inhibitors emerge from Glenmark R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...